Fig. 1. Structures of compounds used in this study. (A) Endogenous ligands acetate and propionate. (B) Phenylacetyl aminothiazole, PAAT. (C) Compound 110; 2-methyl-4-(3-methylpiperidin-1-yl)-7-(phenylsulfonyl)-5H-pyrrolo[3,2-d]pyrimidine-6-amine. (D) Compound 187; 4-[(2R,6S)-2,6-dimethylmorpholin-4-yl]-7-(2-fluorobenzenesulfonyl)-2-methyl-5H-pyrrolo[3,2-d]pyrimidin-6-amine.
© Biomolecules & Therapeutics
